Cross-Sector entity
Monash IVF is most often covered alongside Genesis Capital, which appears in 2 of these 2 stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 6 original sources each.
2 verified stories tracked
Last mentioned: Jun 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Monash IVF is most often covered alongside Genesis Capital, which appears in 2 of these 2 stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. The tracked stories average 6 original sources each. Monash IVF appears in 2 tracked Cross-Sector stories from June 12, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Monash IVF. Shared-story counts are live from our verified record — not editorial picks.
Monash IVF cuts FY26 profit guidance to $17-18M, citing a 4.7% drop in ART cycles, while fending off a $0.90 takeover bid. The financial story now hinges on cost-cutting, international growth, and the possibility of a renewed offer.
Monash IVF’s profit downgrade and a high-profile embryo mix-up signal deeper turmoil in Australia’s ART market, with biotech and pharma implications for fertility drug and device manufacturers.
